Abstract:BACKGROUND & OBJECTIVE:Studies have revealed that overexpression of p53 protein has close relation to induction of drug resistance in cancer patients and it can be used as a predictor for chemosensitivity of tumor. Recently, it has been found that specific p53 antibody (p53-Ab) presented in the serum of cancer patients with p53 protein overexpression. Furthermore, the presence of serum p53-Ab is closely correlated with p53 protein overexpression. Thus, serum p53-Ab could theoretically be useful in predicting chemosensitivity in cancer patients. In the present study, we investigated whether preoperative serum p53-Ab is correlated with the postoperative chemosensitivity of esophageal cancer, which was analyzed using in vitro drug response assay.METHOD:Serum analysis of p53 antibodies was performed by enzyme-linked immunosorbent assay (ELISA) in 38 patients with esophageal cancer preoperatively, then surgically resected specimens were analyzed for their chemosensitivity to cisdichlorodiammineplatinum (DDP),5-fluorouracil (5-FU), and Adriamycin (ADM) by in vitro drug response assay MTT colorimetry.RESULTS:Serum p53-Ab was present in 47.3% of the patients with esophageal cancer. The positive rate of serum p53-Abs in patients was significantly different from that in healthy blood donors (P< 0.01). The positive rate of serum p53-Ab was 25%(5/20) for the patients at stage I and II, and 72.2%(13/18) for the patients at stage III and IV.A significant correlation between serum p53-Ab positive rate and TNM stage was observed (P< 0.05). The positive rate of serum p53-Ab were 21.5%(3/14), 50%(6/12), 75% (9/12) for the patients with well, moderately,and poorly differentiated tumors, respectively. There was significant correlation between serum p53-Ab positive rate and tumor differentiation (P< 0.05). The chemosensitivity to DDP, 5-FU, and ADM (11.1%,16.1%,and 16.1%, respectively) of the patients with positive serum p53-Ab was significantly lower than that of the patients with negative p53-Ab (60%, 45%, and 35%; P< 0.01,P< 0.05, and P< 0.05, respectively).CONCLUSION:p53-Ab is not only a prognostic marker for patients with esophageal cancer, but also a predictor of their response to chemotherapy.

The Presence of Serum Anti-p53 Antibodies from Patients with Invasive Ductal Carcinoma of Breast: Correlation to Other Clinical and Biological Parameters

[Expression and Clinical Significance of Ser10 Phosphorylated P27(kip1) Protein in Human Breast Carcinoma].

The Potential for Serum P53 to Predict the Response to Chemotherapy of Patients with Gastric Cancer

Detection of serum anti-p53 antibodies from patients with ovarian cancer in China: correlation to clinical parameters.

The expressing signification of estrogen receptorβ in breast cancer

Clinical Significance of P53 Expression in Colorectal Cancer Patients

[P53 Protein Expression in HER2-negative Breast Invasive Ductal Carcinoma].

The Expression and Significance of Gadd45a and P53 in Patients with Breast Cancer

The Expression of P16 and P53 Protein and Their Significance in Breast Carcinoma

Expression and Significance of P51 Gene in Breast Cancer

Serum P53 Protein and Anti-P53 Antibodies Are Associated with Increased Cancer Risk: a Case–control Study of 569 Patients and 879 Healthy Controls

Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival

Expressions of DAPK, p53 and Bcl-2 proteins in breast carcinoma tissues and their correlation

[Correlation Between Serum P53 Antibody and Chemosensitivity in Patient with Esophageal Cancer].

Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.

Clinical Pathologic Status and Expression of Tumor Markers in 5,000 Chinese Breast Cancers

P53 Protein Expression Levels in Stage I Breast Cancer and Its Relationship to Clinico - Pathologic Parameters

Expression of C-Erbb-2,p53,pcna and Nm23 Proteins in Breast Cancer and Their Clinical Significance

Expression of p53 and significance of HPV 16/18 infection in invasive ductal carcinoma

Overexpression of P53 is prognostic for aromatase inhibitor resistance in early stage postmenopausal patients with ER-positive breast cancer

Relationship Between Serum Anti-P53 Antibody and Clinical Characteristics of Primary Hepatic Carcinoma